Zynerba Pharmaceuticals (ZYNE) Stock Rises 18%; Rated Strong Buy

 

Zynerba Pharmaceuticals Inc (ZYNE) stock up 18% Tuesday and has gained 21.08% over the last 12 months. The average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives ZYNE stock a score of 75 out of a possible 100.

That score is chiefly influenced by a long-term technical score of 99. ZYNE’s score also includes a short-term technical score of 73. The fundamental score for ZYNE is 53. In addition to the average rating from Wall Street analysts, ZYNE stock has a mean target price of $21.25. This means analysts expect the stock to climb 55.45% over the next 12 months.

Click Here to get the full Stock Score Report on Zynerba Pharmaceuticals Inc (ZYNE).

What’s Happening with ZYNE Stock Today

Zynerba Pharmaceuticals Inc (ZYNE) stock has risen 18.09% while the S&P 500 has gained 0.49% as of 10:40 AM on Tuesday, Jun 11. ZYNE has gained $2.09 from the previous closing price of $11.58 on volume of 2,673,826 shares. Over the past year the S&P 500 has risen 4.27% while ZYNE has gained 21.08%. ZYNE lost -$2.27 per share in the over the last 12 months.

Symbols: ZYNE

You May Also Like